A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)

A. Rullan, D. R. Adkins,P. Bossi, E. E. W. Cohen, A. Daste,K. J. Harrington,C. Le Tourneau, L. F. Licitra, N. Little, T. Morris, C. H. H. Ottensmeier, M. Reinwald, T. Rutkowski

Annals of Oncology（2022）

引用 0|浏览0